X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7407) 7407
Book Review (1003) 1003
Publication (688) 688
Book Chapter (46) 46
Dissertation (44) 44
Conference Proceeding (32) 32
Government Document (30) 30
Magazine Article (3) 3
Newsletter (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5372) 5372
humans (4922) 4922
her2 (4781) 4781
female (3849) 3849
oncology (3606) 3606
breast cancer (3444) 3444
trastuzumab (2072) 2072
cancer (2032) 2032
receptor, erbb-2 - metabolism (1955) 1955
middle aged (1804) 1804
immunohistochemistry (1661) 1661
breast neoplasms - pathology (1654) 1654
expression (1535) 1535
aged (1502) 1502
adult (1441) 1441
receptor, erbb-2 - genetics (1424) 1424
breast neoplasms - metabolism (1347) 1347
prognosis (1274) 1274
breast neoplasms - drug therapy (1220) 1220
chemotherapy (1183) 1183
breast neoplasms - genetics (1153) 1153
animals (1134) 1134
cell line, tumor (1025) 1025
therapy (1004) 1004
tumors (981) 981
gene amplification (957) 957
pathology (956) 956
breast-cancer (948) 948
skin and connective tissue diseases (945) 945
epidermal growth factor (886) 886
metastasis (864) 864
analysis (822) 822
male (809) 809
research (807) 807
mice (803) 803
carcinoma (794) 794
medicine & public health (794) 794
her2/neu (776) 776
survival (762) 762
care and treatment (751) 751
aged, 80 and over (738) 738
cell biology (697) 697
in-situ hybridization (679) 679
monoclonal-antibody (653) 653
antineoplastic agents - therapeutic use (647) 647
amplification (637) 637
gene expression (634) 634
genetic aspects (602) 602
proteins (599) 599
overexpression (585) 585
growth-factor receptor (581) 581
gene expression regulation, neoplastic (572) 572
egfr (567) 567
biochemistry & molecular biology (555) 555
erbb-2 protein (551) 551
in situ hybridization, fluorescence (533) 533
treatment outcome (514) 514
receptor (500) 500
health aspects (497) 497
neoplasm staging (492) 492
receptor, erbb-2 - analysis (492) 492
antibodies, monoclonal, humanized (491) 491
neoplasms (486) 486
biomarkers, tumor - metabolism (482) 482
adjuvant chemotherapy (470) 470
cells (468) 468
receptor, erbb-2 - antagonists & inhibitors (461) 461
article (460) 460
her-2/neu (439) 439
retrospective studies (438) 438
growth (436) 436
gastric cancer (433) 433
receptor, erbb-2 - biosynthesis (427) 427
antineoplastic agents - pharmacology (425) 425
cancer research (415) 415
estrogen-receptor (409) 409
resistance (408) 408
apoptosis (400) 400
cancer therapies (398) 398
signal transduction (398) 398
antineoplastic combined chemotherapy protocols - therapeutic use (384) 384
biomarkers, tumor - analysis (378) 378
breast neoplasms - mortality (378) 378
kinases (378) 378
lapatinib (377) 377
disease-free survival (373) 373
biomarkers, tumor - genetics (368) 368
estrogen (360) 360
erbb2 (357) 357
medicine, research & experimental (357) 357
receptor, erbb-2 - immunology (356) 356
medical prognosis (353) 353
receptors, estrogen - metabolism (349) 349
development and progression (348) 348
breast neoplasms - diagnosis (346) 346
genes, erbb-2 (342) 342
pharmacology & pharmacy (340) 340
antibodies, monoclonal - therapeutic use (328) 328
phosphorylation (321) 321
metastatic breast-cancer (320) 320
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7331) 7331
French (59) 59
German (46) 46
Japanese (28) 28
Chinese (17) 17
Spanish (15) 15
Korean (12) 12
Polish (10) 10
Russian (6) 6
Portuguese (2) 2
Turkish (2) 2
Persian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Discovery, ISSN 2159-8274, 09/2011, Volume 1, Issue 4, pp. 352 - 365
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring... 
CELL LUNG-CANCER | BREAST-CANCER | GEFITINIB | ACTIVATION | GROWTH-FACTOR-RECEPTOR | MET AMPLIFICATION | ONCOLOGY | INDUCED APOPTOSIS | PHASE-II | MUTATIONS | EGFR | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Receptor, ErbB-2 - metabolism | Apoptosis - genetics | BH3 Interacting Domain Death Agonist Protein - genetics | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Receptor, Epidermal Growth Factor - metabolism | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Female | Membrane Proteins - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Retrospective Studies | BH3 Interacting Domain Death Agonist Protein - metabolism | Oncogenes | Apoptosis Regulatory Proteins - biosynthesis | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Apoptosis Regulatory Proteins - metabolism | Phosphatidylinositol 3-Kinases - genetics | Membrane Proteins - biosynthesis | Animals | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Cohort Studies | Index Medicus | oncogene addiction | apoptosis | HER2 | BIM
Journal Article
Theranostics, ISSN 1838-7640, 2016, Volume 6, Issue 2, pp. 262 - 271
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 5/2008, Volume 35, Issue 5, pp. 1008 - 1018
The expression of human epidermal growth factor receptor-2 (HER2) receptors in cancers is correlated with a poor prognosis. If assessed in vivo, it could be... 
Molecular imaging | Medicine & Public Health | Orthopedics | Oncology | Breast cancer | Nuclear Medicine | HER2 | Imaging / Radiology | Cardiology | F-18 | PET | Radiology | Tomography | Rodents | Cancer | Radioactivity | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2017, Volume 23, Issue 3, pp. 636 - 648
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We... 
TUMOR-INFILTRATING LYMPHOCYTES | KAPPA-B ACTIVATION | ONCOLOGY | GROWTH | ACQUIRED-RESISTANCE | HER2 RECEPTOR | ANTIBODY | NECROSIS-FACTOR-ALPHA | CHRONIC INFLAMMATION | UP-REGULATION | CELL-LINE | Humans | Tumor Necrosis Factor-alpha - genetics | Neoplasm Proteins - antagonists & inhibitors | Stomach Neoplasms - pathology | Maytansine - pharmacology | Recombinant Fusion Proteins - metabolism | Immunoconjugates - pharmacology | Mucin-4 - biosynthesis | RNA Interference | Tumor Necrosis Factor-alpha - immunology | Female | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Trastuzumab - metabolism | Trastuzumab - therapeutic use | Antibody-Dependent Cell Cytotoxicity | Maytansine - analogs & derivatives | Breast Neoplasms - drug therapy | Mucin-4 - genetics | Antineoplastic Agents, Immunological - metabolism | Antineoplastic Agents, Immunological - pharmacology | Drug Synergism | Up-Regulation - drug effects | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Signal Transduction - drug effects | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Mice, Nude | Tumor Necrosis Factor-alpha - physiology | Cell Line, Tumor | Breast Neoplasms - mortality | Neoplasm Proteins - analysis | Mice | Receptor, ErbB-2 - analysis | Mucin-4 - physiology | Drug Resistance, Neoplasm - physiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Binding | Immunohistochemistry | Immunoglobulins | Toxicity | Blocking antibodies | Antibodies | Cytotoxicity | Breast cancer | siRNA | Tumor cell lines | Tumor necrosis factor-α | Patients | ErbB-2 protein | Design engineering | Mucin | Experimental design | Cell lines | Biomarkers | Breast | Genetic engineering | Bioindicators | Trastuzumab | Tumors | Cancer | Index Medicus
Journal Article
Molecular Cancer, ISSN 1476-4598, 04/2014, Volume 13, Issue 1, pp. 92 - 92
Journal Article
MEDICINE, ISSN 0025-7974, 06/2019, Volume 98, Issue 26, pp. e15872 - e15872
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer accounts for similar to 20% of invasive breast cancers and is associated with poor... 
trastuzumab | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | single-cell RNA-Seq | CARDIOTOXICITY | RECEPTOR | HER2+breast cancer | transcriptome profile | trastuzumab-mediated cardiotoxicity | TCGA | Pharmacogenetics | Research | Oncology, Experimental | Cancer
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2013, Volume 140, Issue 1, pp. 93 - 104
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 40 - 48
Journal Article